Long-term Follow-up and Monitoring — MCQs
All of the following statements about HRT (hormone replacement therapy) are true except:
Which of the following is not true regarding estrogen use in postmenopausal osteoporosis management?
While investigating a case of gynecomastia, all of the following hormone levels are estimated, except:
Which of the following compounds has been studied as a potential male contraceptive?
What is the preferred treatment of complete uterine prolapse in a female who has completed her family?
Left Internal Mammary Artery (LIMA) has become the conduit of choice for Left Anterior Descending (LAD) artery during coronary artery bypass grafting because:
What is the significance of a 2-year post-treatment surveillance period in paucibacillary leprosy?
What term is used for a patient who is kept under observation in a hospital for a short period (typically less than 48 hours) to determine if formal admission is necessary?
In your STI clinic, standardized treatment kits are available for different conditions based on clinical presentation and likely pathogens. A 22-year-old female comes to the STI clinic with minimal vaginal discharge. On speculum examination, erosions are seen on the cervix. Which of the following treatment kit should be given to this patient?
A multidisciplinary team is developing protocols for adolescent gender-affirming care. When evaluating the appropriateness of GnRH analog therapy versus immediate cross-sex hormones in a 16-year-old with persistent gender dysphoria (Tanner stage 5), which factor most strongly supports proceeding directly to cross-sex hormones?
Long-term Follow-up and Monitoring Indian Medical PG Practice Questions and MCQs
Question 1: All of the following statements about HRT (hormone replacement therapy) are true except:
- A. It increases the risk of coronary artery disease
- B. It increases bone mineral density
- C. It increases the risk of breast cancer
- D. It increases the risk of endometrial cancer (Correct Answer)
Explanation: ***It increases the risk of endometrial cancer*** - This statement is only true for **unopposed estrogen** therapy in women with an intact uterus; combined HRT (estrogen plus progesterone) significantly **reduces** this risk. - The addition of **progesterone** to estrogen HRT is protective against endometrial hyperplasia and cancer. *It increases the risk of coronary artery disease* - Studies have shown that HRT, particularly when initiated several years after menopause, can **increase the risk of cardiovascular events**, including coronary artery disease. - The **Women's Health Initiative (WHI)** study highlighted these risks, especially in older women starting HRT. *It increases bone mineral density* - Estrogen is crucial for maintaining bone density, and HRT can **slow down bone loss** and **reduce the risk of osteoporosis and fractures** in postmenopausal women. - This is a well-established benefit of HRT for bone health. *It increases the risk of breast cancer* - Combined estrogen-progestin HRT has been consistently shown to **increase the risk of breast cancer**, especially with prolonged use (more than 3-5 years). - This increased risk is a significant concern when considering HRT.
Question 2: Which of the following is not true regarding estrogen use in postmenopausal osteoporosis management?
- A. Improves bone density
- B. Lowers breast cancer risk (Correct Answer)
- C. Increases thromboembolism risk
- D. May cause endometrial hyperplasia
Explanation: ***Lowers breast cancer risk*** - Estrogen use, particularly **combined estrogen-progestin therapy**, actually **increases** the risk of breast cancer, rather than lowering it [1]. - This increased risk is a significant concern and a primary reason why estrogen therapy is not a first-line treatment for osteoporosis [1]. *Improves bone density* - Estrogen therapy is known to **prevent bone loss** and **increase bone mineral density** in postmenopausal women by inhibiting osteoclast activity [1]. - This effect is beneficial in reducing the risk of osteoporotic fractures [1], [2]. *Increases thromboembolism risk* - Estrogen therapy significantly **increases the risk of venous thromboembolism (VTE)**, including deep vein thrombosis and pulmonary embolism. - This is a well-established adverse effect and a contraindication in women with a history of thrombotic events. *May cause endometrial hyperplasia* - Unopposed estrogen therapy can **stimulate endometrial proliferation**, leading to **endometrial hyperplasia** and an increased risk of endometrial cancer. - This is why progestin is typically added to estrogen therapy in women with an intact uterus.
Question 3: While investigating a case of gynecomastia, all of the following hormone levels are estimated, except:
- A. Lutenizing hormone
- B. Prolactin
- C. Follicle stimulating hormone (Correct Answer)
- D. None of the options
Explanation: ***Follicle stimulating hormone*** - While **FSH** levels can be assessed in cases of infertility or hypogonadism, they are generally **not a primary assessment** for gynecomastia. - The direct hormonal imbalance causing gynecomastia typically involves other hormones like testosterone, estrogen, LH, and prolactin. *Lutenizing hormone* - **LH** levels are crucial in assessing **gonadal function** and identifying the cause of altered testosterone production, which is directly linked to gynecomastia [1]. - Elevated or suppressed LH can indicate primary or secondary hypogonadism affecting the **testosterone-estrogen balance**. *Prolactin* - **Prolactin** levels are important to rule out **hyperprolactinemia**, which can lead to hypogonadism and subsequently gynecomastia [1]. - A **prolactinoma** (prolactin-secreting tumor) can suppress GnRH, leading to reduced testosterone and an increased estrogen-to-androgen ratio [1]. *None of the options* - This option is incorrect because there is a specific hormone (FSH) among the choices that is **less commonly estimated** in the initial workup for gynecomastia compared to LH and prolactin. - The workup for gynecomastia commonly involves assessment of other hormones like **testosterone** and **estrogen** along with LH and prolactin [1].
Question 4: Which of the following compounds has been studied as a potential male contraceptive?
- A. Quinesterol
- B. Saheli
- C. MALA - N
- D. Gossypol (Correct Answer)
Explanation: ***Gossypol*** - **Gossypol** is a natural compound derived from cotton plants that has been extensively studied for its **male contraceptive** properties due to its effect on sperm production. - Research has shown that gossypol inhibits **spermatogenesis** by affecting various enzymes and processes within the testes, leading to reduced sperm count and motility. However, its use has been limited due to concerns about potential side effects, including **hypokalemia** and irreversible infertility in some individuals. *Quinesterol* - **Quinesterol** is a **synthetic estrogen** primarily used as a component of oral contraceptives for women. - Its mechanism of action involves suppressing ovulation and altering the endometrial lining, making it unsuitable as a male contraceptive. *Saheli* - **Saheli**, also known as Centchroman or Ormeloxifene, is a **non-steroidal oral contraceptive** developed in India and is used for women. - It acts as a **selective estrogen receptor modulator (SERM)** in the uterus, preventing implantation, and is not designed or effective for male contraception. *MALA-N* - **MALA-N** (Norethisterone enanthate or NET-EN) is a **long-acting injectable progestogen contraceptive** used for women in India. - It works by suppressing ovulation, thickening cervical mucus, and altering the endometrium, making it unsuitable for male contraception.
Question 5: What is the preferred treatment of complete uterine prolapse in a female who has completed her family?
- A. Vaginal hysterectomy (Correct Answer)
- B. Pessary
- C. Le Forte's repair
- D. Sling surgery
Explanation: ***Vaginal hysterectomy*** - This is the **definitive surgical treatment** for complete uterine prolapse in women who have completed their family and no longer desire fertility. - It involves removing the uterus through the vagina and can be combined with other repairs for associated pelvic organ prolapse. *Pessary* - A pessary is a **non-surgical management option** that can provide symptomatic relief for prolapse, but it doesn't cure the underlying condition. - While suitable for some, especially those who are not surgical candidates or prefer conservative management, it's not the "preferred treatment" for a complete cure in a woman who has completed her family. *Le Forte's repair* - **Le Forte's colpocleisis** is a surgical procedure that involves partially or completely closing the vaginal canal, suitable for severe prolapse in women who have no desire for future vaginal intercourse. - It is an effective treatment for advanced prolapse but is generally reserved for elderly, frail women, or those who are not candidates for more extensive reconstructive surgery, and it might not be the initial preferred choice for all women who have completed families. *Sling surgery* - Sling surgery, such as a **mid-urethral sling**, is primarily used to treat **stress urinary incontinence** and not uterine prolapse. - While prolapse and incontinence can co-exist, sling surgery alone will not correct complete uterine prolapse.
Question 6: Left Internal Mammary Artery (LIMA) has become the conduit of choice for Left Anterior Descending (LAD) artery during coronary artery bypass grafting because:
- A. Atherosclerosis is never seen in this vessel
- B. It is very easy to harvest
- C. It is close to LAD
- D. Long term patency rates are superior (>90% at 10 years) (Correct Answer)
Explanation: ***Long term patency rates are superior (>90% at 10 years)*** - The superior **long-term patency rates** (over 90% at 10 years) of the **Left Internal Mammary Artery (LIMA)** when anastomosed to the **Left Anterior Descending (LAD) artery** are the primary reason for it being the conduit of choice. - This excellent patency is attributed to its **endothelial** properties and **resistance to atherosclerosis**, contributing to improved patient outcomes and survival. *Atherosclerosis is never seen in this vessel* - While the LIMA is significantly **more resistant to atherosclerosis** compared to saphenous veins, it is not entirely immune. - Atherosclerosis can still occur in the LIMA, though it is far less common and less severe than in other graft conduits. *It is very easy to harvest* - Harvesting the LIMA requires a skilled surgical technique and is **not considered "very easy."** - It involves careful dissection to preserve the conduit's integrity and includes potential complications like **sternal wound infections** due to altered blood supply. *It is close to LAD* - While the anatomical proximity of the LIMA to the LAD is a favorable factor, making the anastomosis geographically convenient, it is **not the primary reason** for its widespread use. - The primary driving factor is the superior long-term patency, which directly impacts patient morbidity and mortality.
Question 7: What is the significance of a 2-year post-treatment surveillance period in paucibacillary leprosy?
- A. To monitor for treatment compliance during active therapy
- B. To assess the effectiveness of multibacillary leprosy treatment protocols
- C. To detect early signs of drug resistance in ongoing treatment
- D. To identify relapses, reactions, and neurological complications after treatment completion (Correct Answer)
Explanation: ***To identify relapses, reactions, and neurological complications after treatment completion*** - The 2-year post-treatment surveillance period for **paucibacillary leprosy** is crucial for monitoring for **relapses** which can occur even after successful multidrug therapy (MDT). - It also allows for the early detection and management of **leprosy reactions** (e.g., Type 1 reversal reactions) and **neurological complications** such as nerve damage, which can develop or progress after treatment completion. *To monitor for treatment compliance during active therapy* - Monitoring for **treatment compliance** occurs *during* the active 6-month MDT period for paucibacillary leprosy, not primarily in the 2-year post-treatment surveillance phase. - While compliance is essential for successful treatment, the post-treatment period is focused on after-effects. *To assess the effectiveness of multibacillary leprosy treatment protocols* - This surveillance period is specifically for **paucibacillary leprosy**, which has a different treatment regimen and surveillance duration (6 months MDT followed by 2 years surveillance) compared to multibacillary leprosy (12 months MDT followed by 5 years surveillance). - The effectiveness of multibacillary treatment protocols would be assessed over a longer period following completion of its own specific MDT. *To detect early signs of drug resistance in ongoing treatment* - Detection of **drug resistance** is typically assessed *during* treatment if a patient is not responding clinically or shows signs of worsening, or in cases of relapse where drug resistance might be suspected as the cause. - While possible, the primary purpose of post-treatment surveillance is broader than just drug resistance; it encompasses all potential adverse long-term outcomes.
Question 8: What term is used for a patient who is kept under observation in a hospital for a short period (typically less than 48 hours) to determine if formal admission is necessary?
- A. Inpatient
- B. Outpatient
- C. Urgent care patient
- D. Observation status (Correct Answer)
Explanation: ***Observation status*** - Patients under **observation status** are monitored in a hospital setting for a short period (typically less than 24-48 hours) to determine if inpatient admission is necessary. - This status is used when the medical condition is uncertain, requiring further evaluation and diagnostic tests to guide treatment decisions. *Inpatient* - An **inpatient** is formally admitted to the hospital for an expected stay of more than 24 hours, often requiring a hospital bed overnight. - This classification is associated with specific billing and care delivery models distinct from observation status. *Outpatient* - An **outpatient** receives medical care at a hospital, clinic, or doctor's office without being admitted for an overnight stay. - Examples include routine check-ups, specialist consultations, and minor surgical procedures performed on the same day. *Urgent care patient* - An **urgent care patient** receives immediate medical attention for illnesses or injuries that are not life-threatening but require prompt treatment. - This care is typically provided in an urgent care clinic, not usually in a hospital setting for 24-hour observation.
Question 9: In your STI clinic, standardized treatment kits are available for different conditions based on clinical presentation and likely pathogens. A 22-year-old female comes to the STI clinic with minimal vaginal discharge. On speculum examination, erosions are seen on the cervix. Which of the following treatment kit should be given to this patient?
- A. Green
- B. Red
- C. Grey (Correct Answer)
- D. Yellow
Explanation: ***Grey*** - A grey kit is indicated for **vaginal discharge** with associated **cervical erosions**, suggesting a treatable bacterial STI like gonorrhea or chlamydia. This kit typically contains antibiotics effective against these pathogens. - The presence of **minimal vaginal discharge** combined with **cervical erosions** points towards cervicitis, for which the grey kit is specifically designed. *Green* - The green kit is typically for the treatment of **vaginal discharge** without specific signs of cervicitis, often targeting common causes like **bacterial vaginosis** or **trichomoniasis**. - It would not specifically address the **cervical erosions** seen in this patient, which are more indicative of cervicitis. *Red* - The red kit is generally used for the treatment of **genital ulcers**, which are typically caused by **herpes simplex virus** or **syphilis**. - While there are erosions, the primary complaint is discharge, and erosions are not typically the sole indicator for a "genital ulcer" kit. *Yellow* - The yellow kit is often designated for **urethral discharge** in males, addressing conditions like **gonorrhea** or **chlamydia** when presenting as urethritis. - This patient is female and presents with **vaginal discharge** and **cervical erosions**, making the yellow kit inappropriate.
Question 10: A multidisciplinary team is developing protocols for adolescent gender-affirming care. When evaluating the appropriateness of GnRH analog therapy versus immediate cross-sex hormones in a 16-year-old with persistent gender dysphoria (Tanner stage 5), which factor most strongly supports proceeding directly to cross-sex hormones?
- A. Parental consent is available
- B. Mental health evaluation shows no contraindications
- C. Completion of pubertal development makes GnRH analogs ineffective (Correct Answer)
- D. Patient expresses strong desire for rapid physical changes
Explanation: ***Completion of pubertal development makes GnRH analogs ineffective*** - **GnRH analogs** are primarily used to suppress the progression of endogenous puberty; once a patient has reached **Tanner stage 5**, biological puberty is complete, rendering suppression redundant. - At this physiological stage, initiating **cross-sex hormones** (gender-affirming hormone therapy) is the appropriate clinical step to align physical characteristics with gender identity. *Parental consent is available* - While **parental consent** is a legal and ethical requirement for treating minors, it does not dictate the physiological choice between suppression and hormone therapy. - Consent is necessary for either **GnRH analogs** or **cross-sex hormones**, but the patient's **Tanner stage** is the medical deciding factor here. *Mental health evaluation shows no contraindications* - A thorough **mental health evaluation** is a prerequisite for all gender-affirming medical interventions to ensure the diagnosis of **gender dysphoria**. - While it confirms readiness for treatment, it does not differentiate which specific endocrine intervention is biologically appropriate for a **Tanner 5** adolescent. *Patient expresses strong desire for rapid physical changes* - **Patient autonomy** and goals are vital, but clinical protocols prioritize developmental staging over the desired speed of changes to ensure safety. - Although **cross-sex hormones** do produce rapid changes compared to analogs, the medical rationale for skipping analogs is the **completion of puberty**, not patient preference.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free